Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi®, is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company’s lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, ‘EVOGUARD.’

Biotechnology

Evofem Biosciences

Saundra Pelletier

Damian Frantz

Ram Gupta

Jamilyn Perez-aragon

Ellen Harris

Amy Raskopf

Rachael Hildebrandt

Ivy Zhang

Tammy Forrester

Kathy Gallo-Doyle

Tim Glennon

Deedee Asuamah

Ellen Thomas

Katherine Mercier

Richard Murawski

Robin Belsaas

Catherine Maher

Brandi Howard

Evofem Biosciences' CEO and Executive Team includes Kelly Culwell and 5 others.

CEO and Executive Team

Leadership Team

CEO and Executive Team

About

Team members

Other teams at Evofem Biosciences

Leadership Team